Featuring perspectives from Dr Rachel N Grisham, including the following topics:

  • Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)
  • A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)
  • Current and future role of avutometinib with defactinib for LGSOC (19:23)
  • A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)


CME information and select publications

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av, eller tillsammans med, Poddtoppen.